Cipher Pharmaceuticals Inc (CPH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cipher Pharmaceuticals Inc (CPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3421
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to moderate plaque psoriasis of the elbows and knee in adults; epuris, an oral retinoid indicated for the treatment of severe nodular and inflammatory acne; and vaniqa, a topical cream indicated to reduce the growth of unwanted facial hair in women. Its pipeline products under development can be used in the treatment of seborrheic dermatitis, plaque psoriasis, chronic pruritus, rheumatoid arthritis, late stage melanoma, and others. Cipher’s pre-clinical compounds are intended for the treatment of melanoma and other cancers. The company provides healthcare professionals with several non-prescription products. Cipher is headquartered in Mississauga, Ontario, Canada.

Cipher Pharmaceuticals Inc (CPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 13
Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 14
Partnerships 15
Cipher Pharma and Italmex Enter into Distribution Agreement 15
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 16
Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 17
Licensing Agreements 18
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 18
Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 19
Cipher Pharma Enters into Licensing Agreement with Pennsylvania State University 20
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 21
Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 22
BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 23
Melanovus Oncology Enters into Licensing Agreement with Penn State Research Foundation 24
Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 25
Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 26
Debt Offering 27
Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 27
Asset Transactions 28
EPI Health Acquires US Commercial Assets from Cipher Pharma 28
Acquisition 29
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 29
Cipher Pharma Acquires Innocutis 31
Cipher Pharmaceuticals Inc – Key Competitors 32
Cipher Pharmaceuticals Inc – Key Employees 33
Cipher Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 10, 2018: Cipher Pharmaceuticals reports Q2 2018 results 35
May 10, 2018: Cipher Pharmaceuticals Reports Q1 2018 Results 37
Feb 28, 2018: Cipher Pharmaceuticals Reports Q4 & FY2017 Results 39
Nov 03, 2017: Cipher Pharmaceuticals Reports Q3 2017 Operating & Financial Results 41
Aug 11, 2017: Cipher Pharmaceuticals reports Q2 2017 financial results 43
Mar 02, 2017: Cipher Pharmaceuticals Reports 2016 Q4 & Year-End Financial Results 44
Corporate Communications 45
Apr 12, 2017: Cipher Pharmaceuticals Proposes Adding Robert Tessarolo and Arthur Deboeck to Board of Directors 45
Mar 20, 2017: Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEO 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cipher Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 13
Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 14
Cipher Pharma and Italmex Enter into Distribution Agreement 15
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 16
Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 17
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 18
Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 19
Cipher Pharma Enters into Licensing Agreement with Pennsylvania State University 20
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 21
Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 22
BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 23
Melanovus Oncology Enters into Licensing Agreement with Penn State Research Foundation 24
Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 25
Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 26
Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 27
EPI Health Acquires US Commercial Assets from Cipher Pharma 28
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 29
Cipher Pharma Acquires Innocutis 31
Cipher Pharmaceuticals Inc, Key Competitors 32
Cipher Pharmaceuticals Inc, Key Employees 33
Cipher Pharmaceuticals Inc, Subsidiaries 34

List of Figures
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Cipher Pharmaceuticals Inc (CPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RegeneRx Biopharmaceuticals Inc (RGRX):企業の財務・戦略的SWOT分析
    Summary RegeneRx Biopharmaceuticals Inc (RegeneRx) is a clinical-stage biopharmaceutical company that designs, researches and develops novel peptides targeted at diseases with unmet medical needs. The company offers clinical trials, science and discovery and business development services. Its busine …
  • True Diagnostics Inc:製品パイプライン分析
    Summary True Diagnostics Inc (True Diagnostics) is a research, development and manufacturing company that offers in-vitro immunodiagnostic test systems and reagents. The company provides trueDX platform technology including trueDX reader, trueDX software, trueDX-TSH test, trueDX-T4 test, trueDX-Gneg …
  • Select Energy Services Inc (WTTR):企業の財務・戦略的SWOT分析
    Select Energy Services Inc (WTTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Alliance Bernstein Private Clients:企業の戦略・SWOT・財務情報
    Alliance Bernstein Private Clients - Strategy, SWOT and Corporate Finance Report Summary Alliance Bernstein Private Clients - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Promentis Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Promentis Pharmaceuticals Inc (Promentis Pharmaceuticals) is a biopharmaceutical company that discovers and develops drugs for the treatment of schizophrenia and other central nervous system disorders. The company also develops therapies for neuropsychiatric disorders. It offers metabotropic …
  • Trumpf GmbH + Co KG:企業の戦略的SWOT分析
    Trumpf GmbH + Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Nordex SE (NDX1):企業の財務・戦略的SWOT分析
    Nordex SE (NDX1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Public Establishment for Electricity Generation and Transmission Co:企業の戦略的SWOT分析
    Public Establishment for Electricity Generation and Transmission Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key empl …
  • Lansen Pharmaceutical Holdings Ltd (503):企業の財務・戦略的SWOT分析
    Summary Lansen Pharmaceutical Holdings Ltd (Lansen), a subsidiary of Cathay International Holdings Ltd is a pharmaceutical that develops, produces and sales specialty prescription western pharmaceuticals for the treatment of rheumatic diseases. The company’s products comprise specialist medicine, Ch …
  • Stabilis Solutions Inc (AETI):企業の財務・戦略的SWOT分析
    Summary Stabilis Solutions Inc (Stabilis Solutions) formerly, Stabilis Energy Inc a subsidiary of Amnor Technologies Inc, is a provider of power delivery solutions. The company's products comprise power distribution and power conversion products. Stabilis Solutions power distribution products compri …
  • SURUGA bank Ltd:企業の戦略・SWOT・財務情報
    SURUGA bank Ltd - Strategy, SWOT and Corporate Finance Report Summary SURUGA bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Attunity Ltd (ATTU):企業の財務・戦略的SWOT分析
    Summary Attunity Ltd (Attunity) is a technology company that provides data management software, cloud database replication solutions, and google cloud database tools. The company provides data management software solutions that enable access, sharing, management, and distribution of data. It offers …
  • Prima BioMed Ltd (PRR)-製薬・医療分野:企業M&A・提携分析
    Summary Prima BioMed Ltd (Prima BioMed) is a biotechnology company that develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company’s products are based on LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It deve …
  • EBOS Group Ltd (EBO):製薬・医療:M&Aディール及び事業提携情報
    Summary EBOS Group Ltd (EBOS) is a healthcare products supplier that markets, sells and distributes healthcare, medical and pharmaceutical products. It also markets and distributes animal care products and offers distribution, warehousing and logistics support to pharmaceutical manufacturers and med …
  • Hokkaido Electric Power Co Inc:発電所・企業SWOT分析
    Hokkaido Electric Power Co Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on ke …
  • Kuwait Reinsurance Company K.S.C.C.:企業の戦略・SWOT・財務情報
    Kuwait Reinsurance Company K.S.C.C. - Strategy, SWOT and Corporate Finance Report Summary Kuwait Reinsurance Company K.S.C.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Sky plc:企業の戦略・SWOT・財務分析
    Sky plc - Strategy, SWOT and Corporate Finance Report Summary Sky plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Cosmo Bio Co Ltd (3386):企業の財務・戦略的SWOT分析
    Summary Cosmo Bio Co Ltd (Cosmo Bio) operates as a medical device company that offers markets research reagents and research instruments. The company’s product categories include antibodies, assay and detection, cells and cell culture, bioactive substances, protein engineering, separation and purifi …
  • Eastern Platinum Limited:企業の戦略・SWOT・財務情報
    Eastern Platinum Limited - Strategy, SWOT and Corporate Finance Report Summary Eastern Platinum Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Marker Therapeutics Inc (MRKR):企業の財務・戦略的SWOT分析
    Summary Marker Therapeutics Inc (Marker Therapeutics) is formerly known as TapImmune Inc is a clinical-stage immuno-oncology company focus on the development of innovative peptide, gene-based immuno therapeutics and vaccines for the treatment of cancer and metastatic disease. The company’s pipeline …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆